China Merchants CSI Biotechnology Theme ETF

Sci-Tech Innovation Board Companies Projected Earnings Growth in 2025, Several Companies Expected to 'Delist'

Hengrui Medicine Subsidiary Receives Approval for SHR-2524 Injection Clinical Trials

BeiGene Reports First Profit in 2025 with Record Sales

Hengrui Medicine Subsidiary Receives Clinical Trial Approval for New CKD Drug

Fosun Henlius's HLX316 Receives NMPA Approval for Clinical Trial

Ful Hong Han Lin's HLX3901 Injection Clinical Trial Application Approved by NMPA

Fosun International Expects to Report Massive Losses of RMB 21.5 to 23.5 Billion in 2025

Hengrui Medicine Subsidiary Receives Approval Notice for Clinical Trials of New Drugs from NMPA

Hengrui Pharmaceutical Obtains Clinical Trial Approval for Hypertension Drug

CICC Publishes Report on Biogen's FY2022 Revenue Meeting Expectations

CCHT to Release FY2025 Annual Earnings on March 12, 2026 After-Market (BJT), Forecast Revenue CNY 13.8 B, EPS CNY 5.27

Hengrui Pharmaceutical Subsidiaries Receive Approval for SHR-A2102 and SHR-8068 Injection Clinical Trials

Hengrui Medicine Simplifies Sales Structure by Eliminating Provincial Management Level

Daiwa Upgrades Taikang Medicine's Revenue Forecast for 2026-2027

Hengrui Medicine Repurchased 623,000 Shares of A-shares

JPMorgan Adjusts Biogen's Target Price

BOA Raises Price Target for BeiGene and Sees Strong 2026 Prospects

BeiGene Reports 2025 Earnings, Transitions to Profitability but Sees Stock Decline

Guotai Junan and DBS Maintain Buy Rating on BeiGene

516930

159837

159849

02158

Yidu Tech has filed a next day disclosure return with HKEX, reporting the repurchase of 1,702,200 shares at an average price of HKD 5.93 per share, totaling HKD 10.09 million. This announcement highlights the company's ongoing share buyback strategy.

- Yidu Tech filed a disclosure return with HKEX regarding a share repurchase of 1,702,200 shares.  
- The repurchase occurred at an average price of HKD 5.93 per share, totaling an aggregate price of HKD 10.09 million.  
- The original content was published on March 12, 2026, via the Issuer Information Service by HKEX.

PUBT

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

YIDU TECH

Yidu Tech files HKEX next day disclosure return disclosing HKD 5.93 per-share buyback price

516500

300347

LabConnect has inaugurated a new central laboratory facility in Wuxi, China, enhancing its global infrastructure to support increasingly complex clinical trials. This facility, developed in collaboration with Teddy Laboratory, will provide integrated testing, logistics, and data oversight services, enabling pharmaceutical and biotech organizations in the Asia-Pacific region to expand their research programs globally. The Wuxi site will support various clinical trial services, including custom kit building and advanced sample logistics, ensuring compliance with international regulatory standards. LabConnect now operates eight global locations, offering a unified partner for central laboratory services.

prnewswire

ChinaAMC CSI Biotechnology Theme ETF

Tigermed

06:50 ETLabConnect amplía su infraestructura de laboratorio central global con una instalación en Wuxi, China

588250

589720

588860

Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor

marketscreener

Penghua SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

SINO BIOPHARM

ICBCCS SSE STAR Biology and Medicine ETF

SIHUAN PHARM PREF OFFER

China Universal 800 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor

159316

159570

562050

159506

520690

516820

159859

159615

159892

Shares of Pharmaron Beijing surged over 13% after announcing a partnership with Eli Lilly, which includes a $200 million investment to manufacture a diabetes and weight-loss drug, orforglipron. The stock closed 8.4% higher, marking its largest single-day rise since September. Eli Lilly aims to gain regulatory approval for the drug in over 40 countries, with the partnership seen as a significant milestone for Pharmaron's business. Eli Lilly is also expanding its supply chain capacity in China, with nearly $6 billion in investments in the country.

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

China Southern Hang Seng Biotech ETF(QDII)

Pharmaron

Eli Lilly

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Pharmaron Beijing Shares Jump After Eli Lilly Pledges $200 Million Investment in Partnership

SinoMab BioScience Ltd. has terminated a 20-year lease for the SinoMab Building at Haiyao Industry Park in Haikou, effective March 12, 2026. This decision aligns with the company's transition to a light-asset manufacturing model, outsourcing production for drug candidates to contract manufacturers. The lease termination will lead to the derecognition of a right-of-use asset valued at approximately RMB35.8 million and is classified as a connected transaction under Hong Kong listing rules.

SINOMAB BIO-B

SinoMab BioScience terminates 20-year lease for Haikou Industry Park property

Gentian Executives Boost Stakes in Employee Share Purchase Round

Tip Ranks

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Proshares UltraShort Nasdaq Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Gentian Executives Boost Stakes in Employee Share Purchase Round

SBIO

IGC Pharma has secured approximately $526,000 in financing through two agreements to enhance liquidity. The first agreement involves a $353,050 original-issue-discount note issued to Vanquish Funding Group, convertible into common stock upon default at a 25% discount. The second agreement is a loan of about $219,000 from One Deck Capital. The funds will be utilized for working capital and general corporate needs.

TradingView

iShares US Pharma

VG Health

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

IGC Pharma Secures ~$526K in Financing, Including Default-Convertible Note With Vanquish

Meilleure Health will hold a board meeting on March 27, 2026, to approve its annual results for the year ending December 31, 2025, and to consider a recommendation for a final dividend payment.

MEILLEUREHEALTH

Meilleure Health sets board meeting to approve annual results and consider final dividend

159898

159883

06929

562600

OrbusNeich Medical Posts Over 5% Rise in 2025 Profit

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ORBUSNEICH

ChinaAMC CSI All Share Health Care Devices ETF

OrbusNeich Medical Posts Over 5% Rise in 2025 Profit

ORBUSNEICH announced its full-year results for the year ended December last year, with a revenue of USD 180 million, an increase of 10% year-on-year. The net profit was HKD 41.899 million, an increase of 5.5% year-on-year; earnings per share were HKD 5.09 cents. A final dividend of HKD 0.12 was declared, compared to HKD 0.10 in the same period last year

AASTOCKS

In the "Performance" report, ORBUSNEICH's annual net profit is USD 41.899 million, an increase of 5.5%, with a final dividend of HKD 0.12

Sensirion Wins Investment Impact Award for High-Impact Expansion in Hungary

iShares US Medical Devices

Direxion S&P Biotech Bear 3X

SPDR S&P Health Equip

Sensirion Wins Investment Impact Award for High-Impact Expansion in Hungary

Allergy Therapeutics Reshapes Major Shareholding Ahead of Potential Hong Kong Listing

BlackRock, Inc.

Hwabao WP CSI Medical Service ETF

iShares Global Healthcare

Bosera Hang Seng Health Care ETF(QDII)

Allergy Therapeutics Reshapes Major Shareholding Ahead of Potential Hong Kong Listing

Goldman Sachs gives Pharmaron a "Buy" rating with a target price of 30.7 yuan. Pharmaron has reached a collaboration with Eli Lilly, which will invest 200 million USD to support the supply of Orforglipron in China. Eli Lilly plans to invest 3 billion USD over the next decade to expand its supply chain capacity in China. Goldman Sachs believes this collaboration reflects Eli Lilly's confidence in the Chinese market and expects Pharmaron to receive a positive market response

PHARMARON

Goldman Sachs gives Pharmaron a "Buy" rating with a target price of 30.7 yuan

Multinational pharmaceutical companies are changing their roles by authorizing local enterprises to distribute products, forming a deeply symbiotic cooperation model. MNCs provide R&D technology and products, while Chinese companies are responsible for nationwide logistics and marketing. This model has evolved from simple distribution to strategic cooperation based on trust and resource exchange, promoting growth for both parties. The collaboration case between Roche and CHINARES PHARMA demonstrates the success of this model, as both sides maximize market potential through resource complementarity

腾讯新闻 - 财经

CHINARES PHARMA

New Competitive Model: Foreign Companies Produce Products, Local Enterprises Provide Channels

China Merchants CSI Biotechnology Theme ETF(159849.SZ)

Yidu Tech files HKEX next day disclosure return disclosing HKD 5.93 per-share buyback price

06:50 ETLabConnect amplía su infraestructura de laboratorio central global con una instalación en Wuxi, China

Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor

Pharmaron Beijing Shares Jump After Eli Lilly Pledges $200 Million Investment in Partnership

SinoMab BioScience terminates 20-year lease for Haikou Industry Park property